ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1646

Abnormal Cerebrovascular Biomarkers in Patients with Rheumatoid Arthritis: Results from a Prospective Study of Cognitive Aging

Maria Vassilaki1, Cynthia Crowson2, John Davis1, Stephanie Duong1, Aivi Nguyen1, David Jones1, Michelle Mielke1, Vemuri Prashanthi1 and Elena Myasoedova1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2021

Keywords: Neuroimaging, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cognitive impairment compared to the general population. This association might be due to chronic systemic inflammation and the associated cardiovascular risk factors (Sood A and Raji MA, 2021). Studies on RA and neuroimaging biomarkers associated with cognitive impairment are limited. The purpose of the study was to examine the associations between RA and dementia/vascular neuroimaging biomarkers in older adults.

Methods: The study included 34 RA cases and 101 participants without RA (≥50 years old) of a prospective study of cognitive aging in community-dwelling older adults, matched 1:3 for age, sex, education, cognitive status at baseline, and the availability of at least one MRI. All RA cases satisfied the 1987 ACR classification criteria. The outcomes of interest were the following neuroimaging biomarkers: global beta-amyloid (Aβ) using PiB-PET; neurodegeneration [glucose brain hypometabolism via FDG-PET, hippocampal volume and cortical thickness via structural MRI], and cerebrovascular pathology via FLAIR-MRI [white matter hyperintensity burden (WMH), subcortical, and cortical infarctions]. All participants had MRI; 47 (12 RA /35 non-RA) had Aβ PET, 45 (10 RA / 35 non-RA) had FDG PET, 55 (17 RA / 38 non-RA) were assessed for infarctions and 49 (14 RA / 35 non-RA) for WMH%TIV. We used Kruskal-Wallis rank-sum and Fisher’s exact tests to compare the neuroimaging measures between the groups.

Results: Participants with vs. without RA did not differ in age, sex, years of education, Apolipoprotein E ε4 carrier status, or major comorbidities. No significant difference was observed between RA cases and non-cases in Aβ burden, and neurodegeneration measures. Although the sample size was small, we observed that RA participants (vs. without RA) had greater mean WMH volume relative to the total intracranial volume (TIV) (mean (SD) % : 1.12 (0.57) % vs 0.76 (0.69) % of TIV, p=0.01), were more likely to have cortical infarctions (4 vs. 1, p = 0.03), and had a higher mean (SD) number of cortical infarctions (0.24 (0.44) vs. 0.05 (0.32) (p=0.02) (Table 1). These associations persisted when the comparisons were limited to cognitively unimpaired individuals.

Conclusion: Patients with RA had more abnormalities in cerebrovascular imaging biomarker measures compared to individuals without RA, despite similar sociodemographics, Apolipoprotein E ε4 carrier status, markers of neurodegeneration, and similar proportion of cognitively impaired patients between the groups. Studies are ongoing to examine these associations further and understand their potential value for prognostication and prevention of cognitive decline and dementia in RA patients.

Reference: Sood A, Raji MA. Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs. Clin Rheumatol. 2021 Apr;40(4):1221-1231

Table 1. Participants’ baseline characteristics.


Disclosures: M. Vassilaki, Roche, 5, Roche, 2, Biogen, 5, Abbott Laboratories, 12, Equity ownership in Abbott Laboratories, Johnson and Johnson, 12, Equity ownership in Johnson and Johnson, Medtronic, 12, Equity ownership in Medtronic, Amgen, 12, Equity ownership in Amgen; C. Crowson, None; J. Davis, Pfizer, 5; S. Duong, None; A. Nguyen, None; D. Jones, None; M. Mielke, Biogen, 2; V. Prashanthi, Miller Communication Inc., 6; E. Myasoedova, None.

To cite this abstract in AMA style:

Vassilaki M, Crowson C, Davis J, Duong S, Nguyen A, Jones D, Mielke M, Prashanthi V, Myasoedova E. Abnormal Cerebrovascular Biomarkers in Patients with Rheumatoid Arthritis: Results from a Prospective Study of Cognitive Aging [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/abnormal-cerebrovascular-biomarkers-in-patients-with-rheumatoid-arthritis-results-from-a-prospective-study-of-cognitive-aging/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/abnormal-cerebrovascular-biomarkers-in-patients-with-rheumatoid-arthritis-results-from-a-prospective-study-of-cognitive-aging/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology